Libervant vs Onyda XR
A plain-English comparison of two neurology drugs that may be accessible via NPP.
Side-by-side
| Libervant | Onyda XR | |
|---|---|---|
| Generic name | diazepam buccal film | clonidine hydrochloride extended-release oral suspension |
| Manufacturer | Aquestive Therapeutics | Tris Pharma |
| Modality | Buccal soluble film benzodiazepine (absorbed through oral mucosa) | Extended-release oral liquid α2-adrenergic agonist (non-stimulant, nighttime dosing) |
| Indication | Neurology (epilepsy rescue therapy) | Child & adolescent psychiatry (ADHD) |
| FDA approval | April 2024 (pediatric 2-5); tentative approval August 2022 for 12+ | May 29, 2024 |
When physicians choose Libervant
Libervant is typically selected when its mechanism and labeled indication fit the disease subtype. It is manufactured by Aquestive Therapeutics and represents a Buccal soluble film benzodiazepine (absorbed through oral mucosa) option in Neurology (epilepsy rescue therapy).
When physicians choose Onyda XR
Onyda XR is typically selected when its mechanism aligns better with disease sub-type, prior therapy failure, or safety profile. It is manufactured by Tris Pharma and represents an Extended-release oral liquid α2-adrenergic agonist (non-stimulant, nighttime dosing) option in Child & adolescent psychiatry (ADHD).
Both drugs - access via NPP
Both Libervant and Onyda XR can be accessed via NPP in most of our covered markets. Choice between them is a clinical decision for the treating physician.
Not medical advice
This comparison is information, not clinical guidance.
Request either drug
Safety, interactions, and handling
Drug interactions: Before dispatch, our clinical team reviews every patient's full medication list against published FDA drug-interaction data. If a significant interaction is identified, we notify the prescribing physician and hold shipment until an alternative dose or timing is confirmed.
Contraindications: This medication is not appropriate for every patient. Refer to the US FDA label for full contraindication list. Patients with active infection, pregnancy, known hypersensitivity, or specific organ-system comorbidities may be excluded. Prescribing-physician judgement applies.
Cold chain and storage: Biologics, monoclonals, and cell/gene therapies require validated cold-chain shipping (2-8°C) with continuous temperature monitoring. On arrival we document temperature logs; out-of-spec shipments are flagged and replaced.
Adverse event reporting: Any adverse event should be reported to both the local national regulator and to Reserve Meds's pharmacovigilance team at [email protected]. We forward serious events to the US manufacturer within 15 days per ICH E2D guidance.
Last medically reviewed: 2026-04-22 by AI Clinical Review Agent (see Trust & Compliance).